Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPAIT: Adjuvant OFS + AI vs Tamoxifen in Young Breast Cancer
NCT02914158Phase 3Recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Mar 2016
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer (2 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Disease-Free Survival at 5 years. Started Mar 2016; status: recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02914158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02914158.